bisnafide

structure in first source

Also Known As:

(R,R)-2,2'-(1,2-ethanediylbis(imino(1-methyl-2,1-ethanediyl)))-bis(5-nitro-1H-benz(de)isoquinolone-1,3-(2H)-dione)dimethanesulfonate; DMP 840; DMP-840; NSC D640430; NSC-D640430; 1H-Benz(de)isoquinoline-1,3(2H)-dione, 2,2'-(1,2-ethanediylbis(imino(1-methyl-2,1-ethanediyl)))bis(5-nitro-, (R-(R*,R*)))-, dimethanesulfonate

Networked: 9 relevant articles (2 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

1.	Neoplasms (Cancer) 01/01/1995 - "Comparative efficacy of DMP 840 against mouse and human solid tumor models." 01/01/1998 - "We enrolled 10 patients with refractory pediatric solid tumors to this Phase I study of DMP 840 given intravenously by short infusion daily for 5 days. " 01/01/1998 - "Phase I study of DMP 840 in pediatric patients with refractory solid tumors." 10/05/1994 - "We evaluated DMP 840 in a human tumor clonogenic assay to estimate what plasma concentrations may be necessary for clinical cytotoxic activity and to determine what types of tumors potentially might be primary targets for initial phase II studies. " 01/01/1994 - "In long-term growth delay studies, DMP 840 induced full regressions in 20 of 20 mice bearing MX-1 tumors, and tumors in one-half of these mice remained regressed for over 5 months. "
2.	Leukemia L1210 04/15/1994 - "Mechanism of action studies in L1210 leukemia cells demonstrated that DMP 840 inhibited the incorporation of thymidine and uridine into DNA and RNA with IC50 values of 0.55 and 0.08 microM, respectively. "
3.	Leukemia 04/15/1994 - "DMP 840 exhibits curative activity in human tumor xenografts, where it shows selectivity for human solid tumors over murine leukemias. " 01/01/1994 - "Against L1210 and P388 murine leukemias, DMP 840 demonstrated little or no activity and was inactive against B16 murine melanoma. " 04/15/1994 - "In contrast to the selectivity found for DMP 840 in vivo, DMP 840 exhibits potent antiproliferative activity in vitro against a variety of human and murine leukemia and solid tumor cell lines in culture, with inhibitory doses that reduce the number of treated cells to one half (IC50) values ranging from 2.3 to 53 nM. DMP 840 was growth inhibitory to three doxorubicin-resistant cell lines with IC50 values also in the nanomolar range. " 04/15/1994 - "A 1-h incubation of DMP 840 (1.22-12 microM) caused 5-log cell kill in KB-3-1 human epidermoid carcinoma, clone A human colon carcinoma, and L1210 murine leukemia cell lines. "
4.	Colonic Neoplasms (Colon Cancer) 01/01/1994 - "Against eight lines of colon adenocarcinoma, DMP 840 caused a high frequency of partial and complete regressions in two lines and significant inhibition of growth in two lines. " 01/01/1994 - "As measured by a tumor growth inhibition assay, i.v. administration of DMP 840 to athymic nude mice at doses at or below the maximum tolerated dose resulted in curative activity against four human solid tumor xenografts, MX-1 mammary carcinoma, CX-1 and DLD-2 colon adenocarcinomas, and LX-1 lung carcinoma, producing full or incomplete regressions and/or percent tumor growth inhibition of > or = 96%. " 01/01/1994 - "DMP 840 was also evaluated against a panel of human tumors comprising colon adenocarcinoma and rhabdomyosarcoma xenografts. "
5.	Carcinoma (Carcinomatosis) 04/15/1994 - "Clonogenic survival experiments showed that DMP 840 was equally cytotoxic to both exponentially growing and quiescent human clone A colon carcinoma cells. " 04/15/1994 - "A 1-h incubation of DMP 840 (1.22-12 microM) caused 5-log cell kill in KB-3-1 human epidermoid carcinoma, clone A human colon carcinoma, and L1210 murine leukemia cell lines. " 01/01/1994 - "As measured by a tumor growth inhibition assay, i.v. administration of DMP 840 to athymic nude mice at doses at or below the maximum tolerated dose resulted in curative activity against four human solid tumor xenografts, MX-1 mammary carcinoma, CX-1 and DLD-2 colon adenocarcinomas, and LX-1 lung carcinoma, producing full or incomplete regressions and/or percent tumor growth inhibition of > or = 96%. "

Related Drugs and Biologics

1.	Naphthalimides
2.	Cytotoxins (Cytolysins)
3.	Uridine
4.	Thymidine
5.	RNA (Ribonucleic Acid)
6.	DNA (Deoxyribonucleic Acid)
7.	Antineoplastic Agents (Antineoplastics)
8.	Doxorubicin (Adriamycin)
9.	Topoisomerase I Inhibitors
10.	Topotecan (Hycamtin)

Related Therapies and Procedures

1.	Therapeutics